Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

November 30, 2020

Study Completion Date

May 15, 2021

Conditions
Hypoxic Pulmonary VasoconstrictionHypoxemiaAcute Respiratory Distress SyndromeSARS-CoV-2 Acute Respiratory Disease
Interventions
DRUG

Effects in oxygenation and hypoxic pulmonary vasoconstriction

"Determination of the anti-inflammatory effect. The anti-inflammatory effect is assessed with serum measurement of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours.~The following measurements will be performed: pulmonary artery systolic and diastolic pressure (PASP, PADP respectively), central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), right ventricular stroke work (RVSW) and left ventricular work (LVSW). Stroke volume (and cardiac output) will be computed using the thermodilution technique averaging three consecutive injections with 10 ml of 0.9% saline solution."

Trial Locations (1)

11800

Adrián Palacios Chavarria, Mexico City

All Listed Sponsors
lead

Unidad Temporal COVID-19 en Centro Citibanamex

OTHER

NCT04998253 - Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2 | Biotech Hunter | Biotech Hunter